An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyrio differ in susceptibility and severity

Medicine

Volumn 84, Issue 1, 2005, Pages 48-60

  Hift, Richard J ^a,b   Meissner, Peter N ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOLEVULINIC ACID; ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABIS; CLONAZEPAM; ERYTHROMYCIN; GONADORELIN AGONIST; HEME ARGINATE; HEME OXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; ORAL CONTRACEPTIVE AGENT; PETHIDINE; PHENYTOIN; PORPHOBILINOGEN; PROGESTERONE; PROTOPORPHYRIN TIN; RIFAMPICIN; RIFATER;

ACUTE INTERMITTENT PORPHYRIA; ADULT; AMINO ACID URINE LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; GENETIC SUSCEPTIBILITY; HORMONE ACTION; HUMAN; INCIDENCE; MALE; MORTALITY; NEUROPATHY; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; PROGNOSIS; PULSE RATE; QUADRIPLEGIA; RECURRENT DISEASE; REMISSION; RISK FACTOR; SEIZURE; SEX DIFFERENCE; SOUTH AFRICA; TREATMENT OUTCOME;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGE FACTORS; ARGININE; EPIDEMIOLOGIC METHODS; FEMALE; HEME; HUMANS; HYPERTENSION; MALE; PORPHYRIA, ACUTE INTERMITTENT; PORPHYRIA, VARIEGATE; PRECIPITATING FACTORS; PSYCHOTIC DISORDERS; REMISSION, SPONTANEOUS; SEX FACTORS; SOUTH AFRICA; TACHYCARDIA;

EID: 12344251028     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.md.0000152454.56435.f3     Document Type: Article

References (64)

1. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med. 1990;150:1469-1474.
2. Andersson C, Nilsson A, Backstrom T. Atypical attack of acute intermittent porphyria-paresis but no abdominal pain. J Intern Med. 2002;252:265-270.
3. Andersson C, Wikberg A, Stegmayr B, Lithner F. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med. 2000;248:319-325.
4. Black KS, Mirsky P, Kalina P, Greenberg RW, Drehobl KE, Sapan M, Meikle E. Angiographic demonstration of reversible cerebral vasospasm in porphyric encephalopathy. Am J Neuroradiol. 1995;16:1650-1652.
5. Bonkovsky HL, Schady W. Neurologic manifestations of acute hepatic porphyria. Semin Liv Dis. 1982;2:108-124.
6. Bonkovsky HL, Tschudy DP, Collins A. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusion of hematin. Proc Natl Acad Sci USA. 1971;62:2725-2729.
7. Bravenboer B, Erkelens DW. Acute hypertension mimicking phaeochromocytoma as main presenting feature of acute intermittent porphyria. Lancet. 1989;2:928.
8. British National Formulary. Normosang (Orphan Europe). Available at: http://www.bnf.org/bnf/bnf/current/doc/82477.htm. Accessed April 5, 2004.
9. Brodie MJ, Moore MR, Thompson GG, Goldberg A, Low RAL. Pregnancy and the acute porphyrias. Br J Obstet Gynaecol. 1977;84:726-731.
10. Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia. 1996;37:230-235.
11. Celik M, Forta H, Dalkilic T, Babacan G. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology. 2002;44:839-841.
12. Cox T. Erythropoietic protoporphyria. J Inherit Metab Dis. 1997;20:258-269.
13. Daimon M, Susa S, Igarashi M, Kato T, Kameda W. Administration of heme arginate, but not hematin, caused anaphylactic shock. Am J Med. 2001;110:240.
14. Dean G. The porphyrias. A story of inheritance and environment. 1st ed. London: Pitman; 1963.
15. Deeg MA, Rajamani K. Normeperidine-induced seizures in hereditary coproporphyria. South Med J. 1990;83:1307-1308.
16. De Siervi A, Rossetti MV, Parera VE, Mendez M, Varela LS, del C Batlle AM. Acute intermittent porphyria: biochemical and clinical analysis in the Argentinean population. Clin Chim Acta. 1999;288:63-71.
17. Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203:437-443.
18. Dixon B. Encephalopathy due to hyponatraemia in acute intermittent porphyria. J R Soc Med. 1997;90:500-501.
19. Doss M, Sixel-Dietrich F, Verspohl F. "Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute porphyrias. J Clin Chem Clin Biochem. 1985;23:505-513.
20. Bales L, Day RS, Blekkenhorst GH. The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int J Biochem. 1980;12:837-853.
21. Elder GH, Hift RJ, Meissner PN. The acute porphyrias. Lancet. 1997;349:1613-1617.
22. Elder GH, Urquhart AJ, De Salamanca RE, Munoz JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet. 1985;2:229-233.
23. Garey JR, Franklin KF, Brown DA, Harrison LM, Metcalf KM, Kushner JP. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterol. 1993;105:165-169.
24. Grandchamp B. Acute intermittent porphyria. Semin Liver Dis. 1998;18:17-24.
25. Herrick AL, McColl KE, Moore MR, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. Lancet. 1989;1:1295-1297.
26. Herrick AL, McColl KE, Wallace AM, Moore MR, Goldberg A. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med. 1990;75:355-363.
27. Hift RJ, Davidson BP, Van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity using the detection of protoporphyrinogen oxidase mutations as a standard. Clin Chem. 2004;50:915-923.
28. Hift RJ, Meissner DM, Meissner PN. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol. 2004;151:465-471.
29. Hift RJ, Meissner PN, Corrigall AV, Ziman MR, Petersen LA, Meissner DM, Davidson BP, Sutherland J, Dailey HA, Kirsch RE. Variegate porphyria in South Africa, 1688-1996-new developments in an old disease. S Afr Med J. 1997;87:722-730.
30. Hunter JA, Khan SA, Hope E, Beattie AD, Beveridge GW, Smith AW, Goldberg A. Hereditary coproporphyria: photosensitivity, jaundice and neuropsychiatric manifestations associated with pregnancy. Br J Dermatol. 1971;84:301-310.
31. Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, Bloomer JR. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 1996;65:269-273.
32. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill; 1989;1305-1365.
33. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992;71:1-13.
34. King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology. 1991;41:1300-1302.
35. Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liv Dis. 1998;18:33-41.
36. Kupferschmidt H, Bont A, Schnorf H, Landis T, Walter E, Peter J, Krahenbuhl S, Meier PJ. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Ann Intern Med. 1995;123:598-600.
37. Lai CW, Hung TP, Lin WS. Blindness of cerebral origin in acute intermittent porphyria. Report of a case and postmortem examination. Arch Neurol. 1977;34:310-312.
38. McColl KE, Thompson GG, Moore MR, Goldberg A. Acute ethanol ingestion and haem biosynthesis in healthy subjects. Eur J Clin Invest. 1980;10:107-112.
39. McDonagh AF, Bissell DM. Porphyria and porphyrinology - the past fifteen years. Semin Liv Dis. 1998;1:3-15.
40. McHugh GJ. Norpethidine accumulation and generalized seizure during pethidine patient-controlled analgesia. Anaesth Intensive Care. 1999;27:289-291.
41. Meissner PN, Hift RJ, Kirsch RE. The porphyrias. In: Arias IM, Boyer JL, Fausto N, Chisari FV, Schachter D, eds. The Liver: Biology and Pathobiology. Philadelphia: Lippincott Williams & Wilkins; 2001.
42. Meyer UA, Schuurmans MM, Lindberg RLP. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liv Dis. 1998;18:43-52.
43. Moore MR, Hift RJ. Drugs in the acute porphyrias-toxicogenetic diseases. Cell Mol Biol (Noisy-le-grand). 1997;43:89-94.
44. Moore MR, McColl KE, Goldberg A. The effects of alcohol on porphyrin biosynthesis and metabolism. Contemp Issues Clin Biochem. 1984;1:161-187.
45. Morales Ortega X, Wolff Fernandez C, Leal Ibarra T, Montana Navarro N, Armas-Merino R. Porphyric crisis: experience of 30 episodes. Medicina (B Aires). 1999;59:23-27.
46. Morris DL, Dudley MD, Pearson RD. Coagulopathy associated with hematin treatment for acute intermittent porphyria. Ann Intern Med. 1981;95:700-701.
47. Mustajoki P. Variegate porphyria. 12 years experience in Finland. Q J Med. 1980;49:191-203.
48. Mustajoki P. Prevention and treatment of acute porphyric attacks. Ann Clin Res. 1985;17:289-291.
49. Mustajoki P, Heinonen J. General anaesthesia in inducible porphyrias. Anaesthesiology. 1980;53:15-20.
50. Mustajoki P, Tenhunen R, Tokola O, Gothoni G. Haem arginate in the treatment of acute hepatic porphyrias. Br Med J. 1986;293:538-539.
51. Pierach CA. Hematin therapy for the porphyric attack. Semin Liv Dis. 1982;2:125-131.
52. Saksena HC, Panwar RB, Rajvanshi P, Sabir M, Suri M. Alcohol and Indian porphyrics. Postgrad Med J. 1991;67:823-824.
53. Savage MW, Reed P, Orrman-Rossiter SL, Weinkove C, Anderson DC. Acute intermittent porphyria treated by testosterone implant. Postgrad Med J. 1992;68:479-481.
54. Singh V, Sud K, Kohli HS, Gupta KL, Sakhuja V. Acute intermittent porphyria: an unusual cause of malignant hypertension. J Assoc Physicians India. 2003;51:225-226.
55. Susa S, Daimon M, Morita Y, Kitagawa M, Hirata A, Manaka H, Sasaki H, Kato T. Acute intermittent porphyria with central pontine myelinolysis and cortical laminar necrosis. Neuroradiology. 1999;41:835-839.
56. Tan CH, Yeow YK. Acute intermittent porphyria (AIP) - an unusual cause of acute confusional state. A case report. Ann Acad Med Singapore. 1988;17:451-453.
57. Taylor RL. Magnesium sulfate for AIP seizures. Neurology. 1981;31:1371-1372.
58. Tenhunen R, Tokola O, Linden IB. Heme arginate: a new stable heme compound. J Pharmacol. 1987;39:780-786.
59. Thunell S, Floderus Y, Henrichson A, Moore MR, Meissner PN, Sinclair J. Alcoholic beverages in acute porphyria. J Stud Alcohol. 1992;53:272-276.
60. Timonen K, Mustajoki P, Tenhunen R, Lauharanta J. Effects of haem arginate on variegate porphyria. Br J Dermatol. 1990;123:381-387.
61. Tokola O, Linden IB, Tenhunen R. The effects of heme arginate and hematin upon the allylisopropylacetamide induced experimental porphyria in rats. Pharmacol Toxicol. 1987;61:75-78.
62. Usalan C, Erdem Y, Altun B, Gursoy M, Celik I, Yasavul U, Turgan C, Caglar S. Severe hyponatremia due to SIADH provoked by acute intermittent porphyria. Clin Nephrol. 1996;45:418.
63. Utz N, Kinkel B, Hedde JP, Bewermeyer H. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology. 2001;43:1059-1062.
64. von und zu Fraunberg M, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltimore). 2005;84:35-47.